Aligos Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $2.2M | $3.6M | $6.2M | $0 | $0 |
| Operating income | -$88.0M | -$89.2M | -$88.1M | -$97.6M | -$128.3M |
| Operating expenses | $90.2M | $93.1M | $103.7M | $111.5M | $132.7M |
| Cash from operations | -$82.5M | -$80.7M | -$79.0M | -$79.4M | -$115.7M |
| Capital expenditure | — | $130,000 | $19,000 | $943,000 | $892,000 |
| Free cash flow | — | -$80.9M | -$79.0M | -$80.3M | -$116.6M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $88.5M | $70.1M | $151.5M | $146.7M | $235.4M |
| Total liabilities | $35.0M | $99.1M | $59.4M | $42.8M | $50.6M |
Shares outstanding 6.2M · Free float 76.4%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.